This is a working overview of cjc-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
== Career == Stobart was born in Cumberland in England in November 1961, the fourth child of Eddie and Nora Stobart. He worked for the family business from his teenage years, joining the management of Eddie Stobart Ltd in 1986. Stobart was Chief Operating Officer of the Stobart Group from 2007 to 2014 and chief executive officer of Eddie Stobart Logistics from 2014 to 2017. He then served as Executive Chairman of GreenWhiteStar Acquisitions from 2019 to 2021 and became Deputy Group CEO of Culina Group in 2021.
=== November === November 13, 2008: Germany Europe's largest economy contracted by 0.5% in the third quarter after GDP fell 0.4% in the second quarter, putting it in recession for the first time in five years.
=== By instrument === A cut by a knife or a scalpel generally scars, though a piercing by a needle does not. In 1976, a 3 by 3 cm scar on a non-diabetic was regenerated by insulin injections and the researchers, highlighting earlier research, argued that the insulin was regenerating the tissue. The anecdotal evidence also highlighted that a syringe was one of two variables that helped bring regeneration of the arm scar. The syringe was injected into the four quadrants three times a day for eighty-two days. After eighty-two days, after many consecutive injections, the scar was resolved and it was noted no scar was observable by the human eye. After seven months the area was checked again and it was once again noted that no scar could be seen. In 1997, it was proven that wounds created with an instrument that are under 2mm can heal scar free, but larger wounds that are larger than 2mm healed with a scar. In 2013, it was proven in pig tissue that full thickness micro columns of tissue, less than 0.5mm in diameter could be removed and that the replacement tissue, was regenerative tissue, not scar. The tissue was removed in a fractional pattern, with over 40% of a square area removed; and all of the fractional full thickness holes in the square area healed without scarring. In 2016 this fractional pattern technique was also proven in human tissue. In 2021, more people were paying attention to the possibility of scar free healing alongside new technologies involving instruments.
== Side effects == Nicotinamide has minimal side effects. Acute liver toxicity has been documented in at least one case with doses over 3000mg, with recommended maximum intake in non liver-impaired individuals being 1500mg. Normal doses are safe during pregnancy. Nicotinamide is contraindicated in individuals diagnosed with liver disease, and/or may cause possible drug interactions.
Sources: en.wikipedia.org
The nape and the anterior third of the body have irregular pale brown and black cross bars, the black forming rings on the neck. The upper lip is pale brown, with black lines on the sutures between the shields. The lower surface of the head is brownish white. The belly and the ventral surface of the tail are blackish.
== Clinical significance == Glycomacropeptide (GMP), generated by cleavage of κ-casein, has been reported to increase digestive efficiency, prevent neonate hypersensitivity to ingested proteins, and inhibit gastric pathogens.
== Adverse effects == Patiromer was generally well tolerated in studies. Side effects that occurred in more than 2% of patients included in clinical trials were mainly gastro-intestinal problems such as constipation, diarrhea, nausea, and flatulence, and also hypomagnesemia (low levels of magnesium in the blood) in 5% of patients, because patiromer binds magnesium in the gut as well.
Supporters of the death penalty state that the claim that the pancuronium prevents the thiopental from working, yet is still capable of causing paralysis, is not based on any scientific evidence and is a drug interaction that has never before been documented for any other drugs.
== Career == From 1967 to 1972, Chrestensen served as production manager of his family's horticultural business in Erfurt. The firm was subsequently nationalized, and from 1972 to 1990 he worked as production manager of the East German state enterprise VEB Erfurter Blumensamen.Following German reunification, from 1990 to 2010 he served as co-managing director of the reconstituted Erfurt seed and plant-breeding company N. L. Chrestensen. From 1990 to 2010, Chrestensen also served as president of the Thuringian Chamber of Industry and Commerce (Industrie- und Handelskammer Thüringen). In that role, he was a co-founder of the Erfurt chamber of commerce after reunification and advocated for Erfurt's inclusion as a stop on Germany's Intercity-Express (ICE) high-speed rail network.
Sources: en.wikipedia.org
ASBMB Avanti Award for Lipid Research (1998) Elected to the American Academy of Arts and Sciences (1999) Heinrich Wieland Prize for Lipid Research (2000) Elected to the National Academy of Sciences (2001) Caledonian Prize from the Royal Society of Edinburgh (2002) Pezcoller-AACR International Award for Cancer Research (2005) Rolf Luft Award of the Karolinska Institute (2009) Pasrow Prize for Cancer Research (2011) Breakthrough Prize in Life Sciences (2013) Jacobaeus Prize for Diabetes Research, from the Karolinska Institute (2013) Elected to the Institute of Medicine of the National Academies (2014) AACR Princess Takamatsu Memorial Lectureship (2015) Ross Prize in Molecular Medicine (2015) Canada Gairdner International Award (2015) Elected to European life sciences academy EMBO (2015) The Association of American Cancer Institutes Distinguished Scientist Award (2015) Thomson Reuter's "The World's Most Influential Scientific Minds 2015". The Wolf Prize in Medicine (2016) The Hope Funds Award of Excellence in Basic Science (2016) Louisa Gross Horwitz Prize (2019) He appeared in the 60 Minutes program "Is sugar toxic?".
Projections to areas caudal to the hypothalamus go through the medial forebrain bundle, the mammillotegmental tract and the dorsal longitudinal fasciculus. Projections to areas rostral to the hypothalamus are carried by the mammillothalamic tract, the fornix and terminal stria. Projections to areas of the sympathetic motor system (lateral horn spinal segments T1–L2/L3) are carried by the hypothalamospinal tract and they activate the sympathetic motor pathway.
Cyclopia, the honeybush, or heuningbos in Afrikaans, is a genus of some 20 species of flowering plants in the legume family Fabaceae, subfamily Faboideae. Species of the genus are native to the southern and southwestern Cape Provinces of South Africa. Its description was published by the French botanist Étienne Pierre Ventenat in 1808. The name Ibbetsonia, published two years later, is regarded as a synonym of this genus; John Sims had commemorated the physiologist Agnes Ibbetson with this name.
=== Youth councils === Under the terms of the Local Government Act 2002, district councils have to represent the interests of their future communities and consider the views of people affected by their decisions. To fulfill that requirement and give young people a say in the decision-making process, many councils have a youth council. In late December 2023, the Ashburton District Council scrapped their youth council, stating they could engage better with younger people online and describing the current youth council as "a youth club where they ate pizza." In early January 2024, the Gore District Council opted to restructure its youth council and ruled out dismantling it. In April 2024, the Whanganui District Council proposed scrapping its youth council by June 2024 as part of budget saving measures.
Nicotine blue oxidoreductase (EC 1.1.1.328, nboR (gene)) is an enzyme with systematic name 3,3'-bipyridine-2,2',5,5',6,6'-hexol:NADP+ 11-oxidoreductase. This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.